

PLATTEN, MICHAEL, PROF. DR. MED.

GENERAL INFORMATION



Chairman/Head

Department of Neurology, Heidelberg University, Mannheim Medical Faculty; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology German Cancer Research Center (DKFZ)
Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

B01

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
2006	Board Certification in Neurology, University of Tübingen
1991 - 1998	Medical School, University of Bonn (Germany), University of London (England) and Harvard Medical School (Boston, USA)

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2006	Habilitation in Neurology, University of Tübingen, Mentor: Johannes Dichgans
1998	MD, Department of Neuropathology, University of Bonn, Supervisor: A. v. Deimling

PROFESSIONAL EXPERIENCE

Year(s)	Experience
2016 - present	Full Professor (W3) of Neurology, Heidelberg University and Chairman, Department of Neurology, University Hospital Mannheim
2015 - 2016	Full Professor (W3) of Neuroimmunology, German Cancer Research Center Heidelberg
2014 - 2016	Vice chair, Department of Neurology, University Hospital Heidelberg
2013 - present	Head Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center
2010 - 2015	Associate Professor (W3) of Experimental Neuroimmunology, University of Heidelberg
2007 - 2013	Head Helmholtz University Young Investigator Group Experimental Neuroimmunology, German Cancer Research Center
2007 - 2014	Vice chair, Department of Neurooncology, University Hospital Heidelberg
2006 - 2007	Attending, Department of Neurology, University of Tübingen
2002 - 2004	Postdoc, Department of Immunology, Stanford University, USA
1999 - 2006	Residency in Neurology, University of Tübingen

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	Qualifications/Roles/Responsibilities
	Editorial Boards (selected)
2017 - present	Editorial Board Journal of ImmunoTherapy of Cancer
2016 - present	Editorial Board Neuro-Oncology
	Honors (selected)
2019	German Cancer Award
2012	Sir Hans Krebs Award
2011	Chica und Heinz Schaller Award
2010	Heinrich Pette Award
2002 - 2004	Emmy Noether Fellow of the German Research Foundation
	Coordinating Functions (selected)
2019 - present	Director of the Mannheim Center for Translational Neuroscience
2018 - present	Coordinator of the Research Topic Immunology and Cancer. DKFZ
2021 - present	Vice chair of the Neurooncology Working Group (NOA) of the German Cancer Society

SELECTED PUBLICATIONS

1. Kilian M*, Sheinin R*, Tan CL, Krämer C, Friedrich M, Kaminitz A, Sanghvi K, Lindner K, Chih YC, Cichon F, Richter B, Jung S, Jähne K, Ratliff M, Prins R, Etmann N, von Deimling A, Wick W, Madi A*, Bunse L*, Platten M*. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. **Cancer Cell** 2023; 41:1-17. *equal contribution
2. Friedrich M*, Sankowski R*, Bunse L*, Kilian M, Green E, Ramallo-Guevara C, Pusch S, Poschet G, Sanghvi K, Hahn M, Bunse T, Münch P, Sonner JK, von Landenberg A, Cichon F, Aslan K, Trobisch T, Schirmer L, Abu-Sammour D, Kessler T, Ratliff M, Schimpf D, Sahm F, Hopf C, Heiland DH, Schnell O, Beck J, Böttcher C, Fernandez-Zapata C, Priller J, Heiland S, Gutcher I, Quintana F, von Deimling A, Wick W, Prinz M* and Platten M*. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. **Nat Cancer** 2021; 2:723–740. *equal contribution
3. Platten M, Bunse I, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens G, Breckwoldt M, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W. A vaccine targeting mutant IDH1 in newly diagnosed glioma. **Nature** 2021; 592:463-468.
4. Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, Núñez NG, De Feo D, Kickingereder P, Fischer M, Green E, Sadik A, Friedrich M, Sanghvi K, Kilian M, Cichon F, Wolf L, Jähne K, von Landenberg A, Bunse L, Sahm F, Schimpf D, Meyer J, Alexander A, Brugnara G, Röth R, Pfliegerer K, Niesler B, von Deimling A, Opitz CA, Breckwoldt MO, Heiland S, Bendszus M, Wick W, Becher B, Platten M. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. **Nat Commun** 2020; 11:931.
5. Sonner JK*, Keil M*, Falk-Paulsen M*, Mishra N, Rehman A, Kramer M, Deumelandt K, Röwe J, Sanghvi K, Wolf L, von Landenberg A, Wolff H, Bharti R, Oezen I, Lanz TV, Wanke F, Tang Y, Brandao I, Mohapatra S, Epping L, Grill A, Röth R, Niesler B, Meuth SG, Opitz CA, Okun JG, Reinhardt C, Kurschus F, Wick W, Bode HB, Rosenstiel P*, Platten M*. Dietary tryptophan links encephalitogenicity of autoreactive T cells with gut microbial ecology. **Nat Commun** 2019; 10:4877. *equal contribution.
6. Bunse L*, Pusch S*, Bunse T*, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger M, Harter P, Ratliff M, Harbottle R, Benner A, Schimpf D, Okun J, Herold-Mende CM, Turcan S, Kaulfuss S, Hess-Stumpff H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suva M, Niemeyer BA, von Deimling A, Wick W, Platten M. Suppression of antitumor T cell immunity by the oncometabolite R-2-hydroxyglutarate. **Nat Med** 2018; 24:1192-1203. *equal contribution
7. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller S, Okun J, Stefanovic S, Riemer AB, Sahin U, Friese M, Beckhove P, von Deimling A, Wick W, Platten M. A vaccine targeting mutant IDH1 induces antitumor immunity. **Nature**. 2014; 512, 324-327
8. Lanz TV, Becker S, Osswald M, Bittner S, Schuhmann MK, Opitz CA, Gaikwad S, Wiestler B, Litzemberger UM, Sahm F, Ott M, Iwantscheff S, Grabitz C, Mittelbronn M, von Deimling A, Winkler F, Meuth SG, Wick W, Platten M. Endothelial protein kinase C β as a therapeutic target stabilizing blood brain barrier disruption in experimental autoimmune encephalomyelitis. **Proc Natl Acad Sci USA**. 2013; 110, 14735-14740
9. Opitz CA, Litzemberger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M. An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation. **Nature**. 2011; 478, 197-203
10. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. **Science**. 2005; 310, 850-855

SELECTED PATENTS

- Means and methods for treating and/or preventing natural Ahr ligand-dependent cancer WO 2013034685 A1
- Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers WO 2013/102641 A1, PCT/EP2013/050048
- Treatment of Kynurenin-producing Tumors with AhR Antagonists PCT/EP2012/067504, US2014/0294860 A1, WO2013/034685, US 9,593,062 B2
- Histone anti-cancer vaccines WO2017009349A1